Life left in CGRP inhibition as Amgen's migraine offering heads to Phase III
This article was originally published in Scrip
Executive Summary
Amgen is to take its calcitonin gene-related peptide (CGRP) receptor inhibitor AMG 334 into Phase III later this year on the back on promising Phase II data in preventing episodic migraine.